Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Mar 13

PMID 38473390

Authors

Maciej Dubaj

Karol Bigosinski

Aleksandra Dembowska

Radoslaw Mlak

Aneta Szudy-Szczyrek

Teresa Malecka-Massalska

Iwona Homa-Mlak

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy in the world and accounts for 15% of primary hemocytopathies, with an ever-increasing number of new cases. It is asymptomatic in 30% of instances; hence, the determination of highly sensitive and specific markers is necessary to make a proper diagnosis. In the last 20 years, miRNAs, involved in regulating the expression of genes responsible for cell proliferation and differentiation, including tumor cells, have been identified as potential diagnostic and prognostic markers. The main aim of the following review was to outline the role of miRNAs in the diagnosis and prognosis of MM, considering their role in the pathogenesis of the disease and identifying their target genes and pathways. For this purpose, publications dating from 2013-2023 have been reviewed. Based on the available data, it is concluded that non-coding RNAs including miRNAs could be potential markers in MM. Furthermore, they may serve as therapeutic targets for certain drugs.

Citing Articles

Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.

Afsar S, Syed R, Khojali W, Masood N, Osman M, Jyothi J Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):297-317.

PMID: 39167168 DOI: 10.1007/s00210-024-03366-3.

Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment.

Gkioka A, Tsota M, Koudouna A, Gkiokas A, Mitropoulou C, Palaiokrassa A Int J Mol Sci. 2024; 25(11).

PMID: 38892251 PMC: 11172882. DOI: 10.3390/ijms25116065.

References

Kazandjian D . Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2017; 43(6):676-681. PMC: 5283695. DOI: 10.1053/j.seminoncol.2016.11.004. View

Li J, Zhang M, Wang C . Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. J Clin Lab Anal. 2020; 34(6):e23233. PMC: 7307343. DOI: 10.1002/jcla.23233. View

Yang C, Liang Y, Shu J, Wang S, Hong Y, Chen K . Long non‑coding RNAs in multiple myeloma (Review). Int J Oncol. 2023; 62(6). PMC: 10198709. DOI: 10.3892/ijo.2023.5517. View

Soliman A, Das S, Ghafar N, Teoh S . Role of MicroRNA in Proliferation Phase of Wound Healing. Front Genet. 2018; 9:38. PMC: 5817091. DOI: 10.3389/fgene.2018.00038. View

Li G, Yin J, Wu Z, Li S, He A, Sun Z . Expression level of miRNA in the peripheral blood of patients with multiple myeloma and its clinical significance. Am J Transl Res. 2021; 13(5):5343-5349. PMC: 8205780. View

Xie B, Li L, Zhang Z, Zhao L, Cheng J, Zhou C . MicroRNA-1246 by Targeting AXIN2 and GSK-3β Overcomes Drug Resistance and Induces Apoptosis in Chemo-resistant Leukemia Cells. J Cancer. 2021; 12(14):4196-4208. PMC: 8176421. DOI: 10.7150/jca.58522. View

Du L, Liu W, Aldana-Masangkay G, Pozhitkov A, Pichiorri F, Chen Y . SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. J Exp Clin Cancer Res. 2022; 41(1):8. PMC: 8725350. DOI: 10.1186/s13046-021-02226-9. View

Rajkumar S, Gupta V, Fonseca R, Dispenzieri A, Gonsalves W, Larson D . Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013; 27(8):1738-44. PMC: 3773463. DOI: 10.1038/leu.2013.86. View

Zhu B, Chen H, Zhang X, Pan Y, Jing R, Shen L . Serum miR-30d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway. Int J Oncol. 2018; 53(5):2131-2144. DOI: 10.3892/ijo.2018.4532. View

10.

Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O . Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS One. 2015; 10(9):e0137294. PMC: 4577078. DOI: 10.1371/journal.pone.0137294. View

11.

Soliman A, Lin T, Mahakkanukrauh P, Das S . Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma. Int J Mol Sci. 2020; 21(20). PMC: 7589124. DOI: 10.3390/ijms21207539. View

12.

Ma H, Shen L, Yang H, Gong H, Du X . Circular RNA circPSAP functions as an efficient miR-331-3p sponge to regulate proliferation, apoptosis and bortezomib sensitivity of human multiple myeloma cells by upregulating HDAC4. J Pharmacol Sci. 2022; 149(1):27-36. DOI: 10.1016/j.jphs.2022.01.013. View

13.

Liang J, Yang Y, He P, Mandizadza O, Zhang W, Lin S . Treatment of multiple myeloma based on autologous stem cell transplant: An overview of systematic reviews. Medicine (Baltimore). 2023; 102(40):e35456. PMC: 10553094. DOI: 10.1097/MD.0000000000035456. View

14.

Menon A, Abd-Aziz N, Khalid K, Poh C, Naidu R . miRNA: A Promising Therapeutic Target in Cancer. Int J Mol Sci. 2022; 23(19). PMC: 9569513. DOI: 10.3390/ijms231911502. View

15.

Wight T, Kang I, Evanko S, Harten I, Chang M, Pearce O . Versican-A Critical Extracellular Matrix Regulator of Immunity and Inflammation. Front Immunol. 2020; 11:512. PMC: 7105702. DOI: 10.3389/fimmu.2020.00512. View

16.

Navarro A, Diaz T, Tovar N, Pedrosa F, Tejero R, Cibeira M . A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget. 2015; 6(3):1874-83. PMC: 4359338. DOI: 10.18632/oncotarget.2761. View

17.

Rajkumar S . Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97(8):1086-1107. PMC: 9387011. DOI: 10.1002/ajh.26590. View

18.

Buranjiang G, Kuerban R, Abuduwanke A, Li X, Kuerban G . MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2. Arch Med Sci. 2019; 15(6):1520-1529. PMC: 6855167. DOI: 10.5114/aoms.2018.77858. View

19.

Allegra A, Cicero N, Tonacci A, Musolino C, Gangemi S . Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma. Cancers (Basel). 2022; 14(7). PMC: 8997050. DOI: 10.3390/cancers14071700. View

20.

Torii C, Maishi N, Kawamoto T, Morimoto M, Akiyama K, Yoshioka Y . miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells. Sci Rep. 2021; 11(1):13502. PMC: 8257582. DOI: 10.1038/s41598-021-92879-5. View